Abstract
Benign prostatic hyperplasia (BPH) is a significant health problem all over the world. This condition will affect most men should they live long enough and can lead to serious complications, such as acute or chronic urinary retention, renal insufficiency, urinary tract infection and sexual dysfunction (Oesterling, 1996; Isaacs, 1990). Symptomatic BPH causes morbidity and can lower the quality of life (QoL) (Hoznek and Abben, 2001; Hegarty et al., 2001). We investigated whether short-term administration of the LHRH antagonist cetrorelix could provide a new treatment for men with BPH (Comaru-Schally et al., 1998).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aoyagi T., Takishima K., Hayakawa M. and Nakamura H. (1996). Gene expression of TGF-α, EGF and IL-6 in cultured renal tubular cells and renal cell carcinoma. Int J Urol, 3, 392–396.
Barry M. and Roehrborn C. (1997). Management of benign prostatic hyperplasia. Annu Rev Med, 48, 177–189.
Begun F.R, Story M.T., Hopp K.A., Shapiro E. and Lawson R.K. (1995). Regional concentration of basic fibroblast growth factor in normal and benign hyperplastic human prostates. J Urol, 153, 839–843.
Cohen P., Peehl D.M., Baker B., Liu F., Hintz R.L. and Rosenfeld R.G. (1994). Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab, 79, 1410–1415.
Comaru-Schally A.M., Brannan W., Schally A.V., Colcolough M. and Monga M. (1998). Efficacy and safety of LHRH antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia. J Clin Endocrinol Metab, 83, 3826–3831.
Culig Z., Hobisch A., Cronauer M.V., Radmayr C, Hittmair A., Zhang J., Thurnher M., Bartsch G. and Klocker H. (1996). Regulation of prostatic growth and function by peptide growth factors. Prostate, 28, 392–405.
De Bellis A., Ghiandi P., Comerci A., Fiorelli G., Grappone C, Milani S., Salerno R., Marra F. and Serio M. (1996). Epidermal growth factor, epidermal growth factor receptor, and transforming growth factor-alpha in human hyperplastic prostate tissue: expression and cellular localization. J Clin Endocrinol Metab, 81, 4148–4154.
Dutcher J.P., Fisher R.I., Weiss G., Aronson E, Margolin K., Louie A., Mier J., Caliendo G., Sosman J.A., Eckardt J.R., Ernest M.L., Doroshow J. and Atkins M. (1997). Outpatient subcutaneous interleukin-2 and interferon-α for metastatic renal cell cancer: 5-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am, 3, 157–162.
Gabrilove J.L., Levine A.C., Kirschenbaum A., Droller M. (1989). Effect of long-acting gonadotropin-releasing hormone analog (leuprolide) therapy on prostatic size and symptoms in 15 men with benign prostatic hypertrophy. J Clin Endocrinol Metab, 69, 629–632.
Godley P. and Kim S.W. (2002). Renal cell carcinoma. Curr Opin Oncol, 14, 280–285.
Gonzalez-Barcena D., Vadillo-Buenfil M., Gomez-Orta F., Fuentes Garcia M., Cardenas-Cornejo I., Graef-Sanchez A., Comaru-Schally A.M. and Schally A.V. (1994). Responses to the antagonistic analog of LHRH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer. Prostate, 24, 84–92.
Hegarty P.K., Hegarty N.J., Fitzpatrick J.M. (2001). Sexual function in patients with benign prostatic hyperplasia. Curr Urol Rep, 2, 292–296.
Henriksson R., Nilsson S., Colleen S., Wersau P., Heising M., Zimmerman R. and Engman K. (1998). Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs. interleukin 2, a-interferon (leucocyte) and tamoxifen. Br J Cancer, 77, 1311–1317.
Hoznek A. and Abbou C.C. (2001). Impact of interventional therapy for benign prostatic hyperplasia on quality of life and sexual function. Curr Urol Rep, 2, 311–317.
Isaacs J.T. (1990). Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. Prostate, 3, 1–7.
Jemal A., Thomas A., Murray T. and Thun M. Cancer statistics. (2002). CA Cancer J Clin, 52, 23–47.
Jungwirth A., Schally A.V., Haimos G., Groot K., Szepeshazi K., Pinski J. and Armatis P. (1998). Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by LHRH antagonists Cetrorelix, somatostatin analog RC-160 and bombesin antagonist RC-3940-II. Cancer, 82, 909–917.
Lepor H., Williford W.O., Barry M.J., Brawer M.K., Dixon CM., Gormley G., Haakenson C, Machi M., Narayan P. and Padley R.J. (1996). The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med, 335, 533–539.
McKiernan J.M. and Lowe F.C. (1997). Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia. South Med J, 90, 509–513.
Motzer R.J., Bander N.H., Nanus D.M. Renal-cell carcinoma. N Engl J Med, 1996, 335, 865–875.
Nickel J.C., Fradet Y., Boake R.C., Pommerville P.J., Perreault J.P., Afridi S.K. and Elhilali M.M. (1996). Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. Can Med Assoc J, 155,1251–1259.
Oesterling J.E. (1996). Benign prostatic hyperplasia: a review of its histogenesis and natural history. Prostate, 6, 67–73.
Papadopoulos I., Rudolph P., Weichert-Jacobsen K., Thiemann O. and Papadopoulou D. (1996). Prognostic indicators for response to therapy and survival in patients with metastatic renal cell cancer treated with interferon-α2β and vinblastine. Urology, 48, 373–378.
Peters C.A. and Walsh P.C. (1987). The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med, 317, 599–604.
Reynolds C.F. III, Frank E., Thase M.E., Houck P.R., Jennings J.R., Howell J.R., Lilienfeld S.O. and Kupfer D.J. (1988). Assessment of sexual function in depressed, impotent, and healthy men: factor analysis of a Brief Sexual Function Questionnaire for men. Psychiat Res, 24, 231–250.
Richie J.P., Kantoff P.W. and Shapiro C.L. (1997). Renal cell carcinoma. In Cancer Medicine, 4th edn, eds, Holland J.F., Frei E. III, Bast R.C Jr, Kufe D.W., Morton D.L. and Weichselbaum R.R., pp. 2085–2096. Baltimore, MD, Williams & Wilkins.
Schally A.V. and Comaru-Schally A.M. (1997a). Hypothalamic and other peptide hormones. In Cancer Medicine, 4th edn, eds, Holland J.F., Frei E. III, Bast R.C Jr, Kufe D.W., Morton D.L. and Weichselbaum R.R., pp. 1067-1086. Baltimore, MD, Williams & Wilkins.
Schally A.V. and Comaru-Schally A.M. (1997b). Rational use of agonists and antagonists of luteinizing hormone-releasing hormone (LHRH) in the treatment of hormone-sensitive neoplasms and gynecologic conditions. Adv Drug Deliv Rev, 28, 157–169.
Schally A.V. and Comaru-Schally A.M. (2000). Hypothalamic and other peptide hormones. In Cancer Medicine, 4th edn, eds, Holland J.F., Frei E. III, Bast R.C. Jr, Kufe D.W., Morton D.L. and Weichselbaum R.R., pp.715–729 Hamilton, Ontario, B.C. Dekker.
Schally A.V., Comaru-Schally A.M., Nagy A., Kovacs M., Szepeshazi K., Plonowski A., Varga J.L. and Haimos G. (2001). Hypothalamic Hormones and cancer. Front Neuroendocrinol, 22, 248–291.
Shapiro E. and Lepor H. (1995). Pathophysiology of clinical benign prostatic hyperplasia. Urol Clin North Am, 22, 285–290.
Sion-Vardi N., Kaneti J., Segal-Abramson T., Giat J., Levy J. and Sharoni Y. (1992). Gonadotropin-releasing hormone specific binding sites in normal and malignant renal tissue. J Urol, 148, 1568–1570.
Sokoloff M.H., deKernion J.B., Figlin R.A. and Belldegrun A. (1996). Current management of renal cell carcinoma. CA Cancer J Clin, 46, 284–302.
Steiner M.S. (1995). Review of peptide growth factors in benign prostatic hyperplasia and urological malignancy. J Urol, 153, 1085–1096.
Wise G.J. and Ostad E. (2001). Hormonal treatment of patients with benign prostatic hyperplasia: pros and cons. Curr Urol Rep, 2, 285–291.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Italia
About this paper
Cite this paper
Comaru-Schally, A.M. (2003). Analogs of Luteinizing Hormone-releasing Hormone in Benign Prostatic Hyperplasia and Advanced Renal Cell Carcinoma. In: Müller, E.E. (eds) Peptides and Non Peptides of Oncologic and Neuroendocrine Relevance. Springer, Milano. https://doi.org/10.1007/978-88-470-2085-6_2
Download citation
DOI: https://doi.org/10.1007/978-88-470-2085-6_2
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-2170-9
Online ISBN: 978-88-470-2085-6
eBook Packages: Springer Book Archive